Bristol-Myers Squibb presents new clinical data at 2017 Liver Meeting

Bristol-Myers Squibb is attending this week's Liver Meeting in Washington, DC, where it is sharing insights into the performance of a number of liver disease therapies.

During the conference, which runs from October 20th to 24th, the company is sharing data on new treatments for nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), among other therapies.

Presentations will include two analyses from a phase II study of BMS-986036 in NASH, which provide further support of non-invasive methods – such as imaging studies and serum Pro-C3 – for assessing liver fibrosis.

Additionally, updated data for Opdivo in HCC generated through the CheckMate-040 trial will be shared, highlighting the finding that formed the basis for the recent US regulatory approval the drug received.

Dr Tom Lynch, executive vice-president and chief scientific officer at Bristol-Myers Squibb, said: "The data being presented at The Liver Meeting demonstrate our commitment to advancing the science in HCC and NASH, two serious liver diseases with unmet medical need."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.